How to Start Menopause Hormone Therapy (HRT)

If symptoms are affecting your quality of life, the next step is an individual review of benefits, risks, and treatment options. This guide explains the main decisions and what to expect after starting.

Why women start hormone therapy at menopause

Most women consider systemic hormone therapy because hot flashes or night sweats are disrupting sleep and daily life. MHT is the most effective treatment for these symptoms ¹. Sleep may improve when night sweats improve, although other sleep problems can still need separate care.

Systemic estrogen also prevents bone loss and reduces fractures while it is used ¹. That can be an additional benefit, but MHT is not prescribed to promise a longer life. A DEXA bone-density scan measures bone density when screening is appropriate. The decision to start MHT should still begin with your main symptoms and personal risk profile.

How you start, and whether you're a candidate

A clinician should review your symptoms, age, time since menopause, personal and family history, current medications, and treatment goals. This review identifies conditions that may make systemic estrogen inappropriate or require specialist input.

For many healthy women with bothersome symptoms who are younger than 60 or within 10 years of menopause, the benefit-risk balance can be favorable ¹, ². This is a general starting point, not an automatic approval rule. Breast-cancer, blood-clot, stroke, gallbladder, and endometrial risks depend on the regimen and the person using it.

• Symptoms and goals

  Identify which symptoms you want to treat and how they affect your sleep, comfort, or daily life.
• Age and timing

  Starting before age 60 or within 10 years of menopause may support a favorable balance, but it does not decide candidacy by itself.
• Medical history

  Discuss unexplained bleeding, hormone-sensitive cancer, blood clots, stroke, heart disease, liver disease, and other relevant conditions.
• Personal preferences

  Consider which benefits matter to you and which risks, side effects, costs, or routines you would find difficult.

Type, route, dose, and duration should be individualized and revisited over time ³. Starting near menopause differs from starting much later. However, one trial supporting the timing hypothesis measured changes in artery-wall thickness rather than heart attacks or strokes ⁴. If you are unsure whether your symptoms are perimenopause, begin with that evaluation.

Choosing your route and format: pill, patch, gel, or local

Hormone therapy includes systemic and local treatments. The right route depends first on the symptom you are treating.

Oral pills, skin patches, and gels are systemic treatments that can treat hot flashes and night sweats. Low-dose vaginal estrogen is a local treatment for vaginal and urinary symptoms, with minimal systemic absorption ¹. It does not treat hot flashes. Observational evidence suggests transdermal patches and gels have a lower blood-clot risk than oral estrogen, but they are not risk-free ⁵.

If you have a uterus, systemic estrogen must be paired with an appropriate progestogen to protect the uterine lining ¹. After a hysterectomy, estrogen can usually be used alone. Low-dose vaginal therapy is managed differently because systemic absorption is minimal. Its role in sexual comfort is covered in our guide to sex after menopause.

What the first few months feel like

Symptom relief often builds over several weeks. Breast tenderness, bloating, or unscheduled bleeding can occur early, depending on the regimen. Ask in advance which effects are expected and when to contact the prescriber.

The first prescription may need adjustment. At follow-up, review symptom relief, side effects, adherence, blood pressure, and any new health concerns ³. Persistent bleeding, heavy bleeding, or bleeding that begins after a period without bleeding may need evaluation rather than a routine dose change.

How long does it take for hormone therapy to start working?

Hot flashes and night sweats often improve over several weeks, although timing varies. If symptoms remain troublesome, the prescriber can review the dose, route, adherence, and other possible causes. Do not change the dose without guidance.

Is it safe? Putting the older headlines in context

The Women's Health Initiative enrolled postmenopausal women with an average age of about 63. Its combined-therapy trial tested oral conjugated equine estrogen with medroxyprogesterone acetate ⁶. Those results remain important, but they should not be generalized to every dose, route, or formulation.

The breast-cancer findings also differed by regimen. Among trial participants with a hysterectomy, estrogen alone was associated with about 22% fewer breast-cancer diagnoses and about 40% fewer breast-cancer deaths in long-term follow-up ⁷. These are relative effects and apply to that trial population and regimen. Combined estrogen plus progestogen was associated with a relative increase of about 28% ⁷.

The WHI combination used conjugated equine estrogen plus medroxyprogesterone acetate. The 2022 North American Menopause Society statement estimated fewer than one additional breast-cancer case per 1,000 women per year of use ¹. Risk differs across regimens. Across about 18 years of WHI follow-up, assignment to hormone therapy did not increase overall mortality ⁸. This does not prove that MHT extends life.

Does hormone therapy cause breast cancer?

Risk differs by regimen and duration. In WHI follow-up, estrogen alone after hysterectomy and combined estrogen plus progestogen had different breast-cancer results ⁷. Discuss your baseline risk and the specific regimen being considered rather than applying one result to all MHT.

In November 2025, the US Food and Drug Administration (FDA) requested removal of cardiovascular-disease, breast-cancer, and probable-dementia statements from MHT boxed warnings ⁹. It retained cardiovascular and breast-cancer information elsewhere in systemic-product labeling. It also retained the endometrial-cancer boxed warning for systemic estrogen used alone. Product labels may be updated at different times, so check the current label. The comprehensive guide explains the evidence in more detail.

What to ask, and where to start

You don't need to walk into that first appointment as an expert. You need a few good questions.

• Am I a candidate, given my history?

  Bring your personal and family history, medication list, and a record of any unexpected bleeding.
• Would a patch or gel suit me better?

  Ask whether a transdermal route makes sense for your symptoms, preferences, and clot risk.
• Is local therapy enough?

  Ask about low-dose vaginal therapy if vaginal or urinary symptoms are your main concern and you do not have hot flashes.
• When will we reassess?

  Know when to review symptom relief, side effects, bleeding, and whether the dose or route should change.